A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs TK 216 (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; First in man
- Sponsors Oncternal Therapeutics, Inc.; Tokalas, Inc.
- 20 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 20 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, nine patients have been enrolled till date.